Valeo Pharma Company Description
Valeo Pharma Inc., a specialty pharmaceutical company, engages in the acquisition, in-licensing brands, and sale of pharmaceuticals and hospital specialty products for unmet medical needs in Canada.
Its product portfolio includes Enerzair Breezhaler, a LABA/LAMA/ICS fixed triple dose asthma drug; Atectura Breezhaler, a LABA/ICS dual combination asthma drug; Redesca, to treat and prevent deep vein thrombosis and pulmonary embolism; Onstryv, for the treatment of Idiopathic Parkinson’s disease; M-Eslon, extended-release morphine sulphate used for pain management; and Yondelis, a soft tissue sarcoma.
It also offers Hesperco, a flavonoid formulation used for immune support; Ethacrynate Sodium; and Amikacin, an antibiotic.
In addition, the company provides Ametop Gel 4% for skin anesthesia prior to injection or cannulation; Sabizabulin, an antiviral and anti-inflammatory agent for the treatment of hospitalized moderate-severe COVID-19 patients at high risk for acute respiratory distress syndrome (ARDS) and death; Simbrinza, ophthalmic drops to treat openangle glaucoma or ocular hypertension; Xiidra, a prescription based eye-drop to treat dry eye disease; and Allerject, a portable voice-activated epinephrine injector for emergency treatment of serious allergic reactions.
Its primary therapeutic areas include respiratory/allergy, ophthalmology, neurology, oncology, and specialty products.
The company was incorporated in 2003 and is based in Kirkland, Canada. As of February 5, 2025, Valeo Pharma Inc. operates as a subsidiary of Xediton Pharmaceuticals Inc.
| Country | Canada |
| Founded | 2003 |
| Industry | Drug Manufacturers - Specialty & Generic |
| Sector | Healthcare |
| Employees | 110 |
| CEO | Al Moghaddam |
Contact Details
Address: 16667 Hymus Boulevard Kirkland, Quebec H9H 4R9 Canada | |
| Phone | 514-694-0150 |
| Website | valeopharma.com |
Stock Details
| Ticker Symbol | VPHIF |
| Exchange | OTCMKTS |
| Share Class | Class A Shares |
| Fiscal Year | November - October |
| Reporting Currency | CAD |
| ISIN Number | CA91915B1085 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Kyle Steiger | Senior Vice President and Chief Commercial Officer |
| Pascal Tougas | Chief Financial Officer |
| Frédéric Dumais | Director of Communications and Investor Relations |
| Guy-Paul Allard | Vice President of Legal Affairs and Corporate Secretary |
| Jean Francois Fournier | Head of Ophthalmology Business Unit |